EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A Pilot Study of Ketotifen in Patients Aged 8–17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia

Chance S Friesen, Valentina Shakhnovich, Paul Toren, Brandon Retke, Jennifer Schurman, Jennifer Colombo, Amanda Deacy, Craig A Friesen, Susan Abdel-Rahman

Pediatric Drugs · 2024-07 · 26 (4) · 451-457

DOI: 10.1007/s40272-024-00628-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Drugs, online erschienen am 21.05.2024. Verfasst von Chance S Friesen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA. Hauptthemen laut MEDLINE: Ketotifen, Dyspepsia, Cross-Over Studies, Eosinophilia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Mast cells have been implicated in abdominal pain-associated disorders of gut-brain interaction, such as functional dyspepsia. As such, ketotifen, a second-generation antihistamine and mast cell stabilizer, could represent a viable treatment option in these conditions. The primary aim of the current pilot study was to assess clinical response to ketotifen and assess pharmacokinetics in youth with functional dyspepsia. METHODS: We conducted a pilot randomized, double-blind, placebo-controlled, cross-over trial of ketotifen in 11 youth with functional dyspepsia and duodenal mucosal eosinophilia with 4 weeks of active treatment at a dose of 1 mg twice daily. Global clinical response was graded on a 5-point Likert Scale. A single plasma sample was obtained at steady state for pharmacokinetic analysis. RESULTS: Ketotifen was not superior to placebo with regard to global clinical response. Only 18% of patients demonstrated a complete or near-complete clinical response. The estimated half-life was 3.3 h. CONCLUSIONS: While ketotifen was not superior to placebo, this study highlights several important challenges for developing drug trials for youth with chronic abdominal pain. Recommendations are made for designing a larger treatment trial for ketotifen in this patient group. CLINICAL TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov: NCT02484248.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetotifenDyspepsiaCross-Over StudiesEosinophiliaHumansPilot ProjectsChildAdolescentDouble-Blind MethodFemaleMaleHistamine H1 AntagonistsIntestinal MucosaAbdominal PainTreatment Outcome

Substanzen

KetotifenHistamine H1 Antagonists

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.
  • Ironwood Pharmaceuticals, Boston, MA, USA.
  • Research Institute, Children's Mercy Kansas City, Kansas City, MO, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA. friesenl@umkc.edu.
  • Health Data Synthesis Institute, Kansas City, MO, USA.

Zitieren

APA

Friesen, C. S., Shakhnovich, V., Toren, P., Retke, B., Schurman, J., Colombo, J., Deacy, A., Friesen, C. A., & Abdel-Rahman, S. (2024). A Pilot Study of Ketotifen in Patients Aged 8–17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia. Pediatric Drugs, 26(4), 451-457. https://doi.org/10.1007/s40272-024-00628-8

Vancouver

Friesen CS, Shakhnovich V, Toren P, Retke B, Schurman J, Colombo J, et al. A Pilot Study of Ketotifen in Patients Aged 8–17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia. Pediatric Drugs. 2024;26(4):451-457. doi:10.1007/s40272-024-00628-8

BibTeX
@article{Friesen2024,
  author = {Friesen, Chance S and Shakhnovich, Valentina and Toren, Paul and Retke, Brandon and Schurman, Jennifer and Colombo, Jennifer and Deacy, Amanda and Friesen, Craig A and Abdel-Rahman, Susan},
  title = {A Pilot Study of Ketotifen in Patients Aged 8–17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia},
  journal = {Pediatric Drugs},
  year = {2024},
  volume = {26},
  number = {4},
  pages = {451--457},
  doi = {10.1007/s40272-024-00628-8}
}
Kostenlos starten →